Redwing Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 16 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 39.91%
- Profit Growth -28.78%
- Ebitda 813.32%
- Net Worth 7.43%
- Total Assets -2.07%
About Redwing Pharma
Redwing Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 July 2008 and has a history of 16 years and six months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Ruchika Jain and Gaurav Jain serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239MH2008PTC184934
-
Company No.
184934
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Jul 2008
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Redwing Pharma Private Limited offer?
Redwing Pharma Private Limited offers a wide range of products and services, including Antibiotic Injection, Piperacillin Tazobactam Injection, Surface Cleaner, Disinfectant Spray, Vitamin Tablets & Capsules, Vitamin C Tablets & Capsules, Folic Acid Tablet.
Who are the key members and board of directors at Redwing Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ruchika Jain
|
Director | 09-Nov-2016 | Current |
|
Gaurav Jain
|
Director | 10-May-2011 | Current |
Financial Performance of Redwing Pharma.
Redwing Pharma Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 39.91% increase. The company also saw a substantial fall in profitability, with a 28.78% decrease in profit. The company's net worth moved up by a moderate rise of 7.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Redwing Pharma?
In 2019, Redwing Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Healthgenic International Private LimitedGaurav Jain is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Redwing Pharma?
Unlock and access historical data on people associated with Redwing Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Redwing Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Redwing Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
